TITLE

Breast cancer prognostic markers: where are we now?

AUTHOR(S)
Gökmen-Polar, Yesim; Badve, Sunil
PUB. DATE
September 2012
SOURCE
MLO: Medical Laboratory Observer;Sep2012, Vol. 44 Issue 9, p22
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses traditional breast cancer prognostic factors and prognostic multigene classifiers used in current clinical decision making and their potential impact on future clinical management. Breast cancer is a heterogeneous disease with diverse morphologies, molecular features and response to therapeutics. It highlights the need for a comprehensive approach that will combine the different modalities and provide individualized prognostic information.
ACCESSION #
79793082

 

Related Articles

  • Theranostic and Molecular Classification of Breast Cancer. Cornejo, Kristine M.; Kandil, Dina; Khan, Ashraf; Cosar, Ediz F. // Archives of Pathology & Laboratory Medicine;Jan2014, Vol. 138 Issue 1, p44 

    Context.-Despite advances in breast cancer management, women continue to relapse and die of breast cancer. Traditionally, evaluation for hormone receptors (estrogen and progesterone), as well as HER2 overexpression, have guided therapy-related decision-making because they are both prognostic and...

  • Breast cancer prognostic markers: an overview of a changing menu. Gökmen-Polar, Yesim; Badve, Sunil // MLO: Medical Laboratory Observer;Oct2015, Vol. 47 Issue 10, p8 

    The article presents information on the prognostic markers of breast cancer. Topics include the traditional prognostic factors such as tumor size, lymph node status, and distant metastases presence, the Nottingham prognostic index (NPI) tool, and traditional molecular markers like estrogen...

  • A New Look at Node-Negative Breast Cancer. HARBECK, NADIA; THOMSSEN, CHRISTOPH // Oncologist;Dec2010 Supplement, Vol. 15, p29 

    Node-negative breast cancer is a prevalent form of the disease worldwide, particularly in regions with rigorous screening and disease awareness efforts. Although there is a common biology between node-negative and node-positive breast tumors, it is still important to specifically address risk...

  • Targeted therapies in breast cancer. Tailoring treatment to the molecular drivers of disease progression. Hicks, David G. // MLO: Medical Laboratory Observer;Jan2012, Vol. 44 Issue 1, p36 

    The article offers information the classification and treatment of breast cancer in the U.S. It offers information on estrogen receptor (ER) that interacts with the ligand, estrogen for activation. It offers information on human epidermal growth factor receptor 2 (HER2) which is located on...

  • Basal-Like Breast Cancer. Leidy, Jennifer; Khan, Ashraf; Kandil, Dina // Archives of Pathology & Laboratory Medicine;Jan2014, Vol. 138 Issue 1, p37 

    Context.-Basal-like breast carcinoma (BLBC) is a distinct molecular subtype of breast carcinoma identified through gene expression profiling studies. Objective.-To provide the clinical background, the histologic profile, and the immunohistochemical profile of these tumors and discuss the current...

  • New Treatment Paradigms in the Management of Metastatic Breast Cancer. Hurvitz, Sara A. // Journal of Managed Care Medicine;2014, Vol. 17 Issue 1, p52 

    No abstract available.

  • Response. Ocana, Alberto; Vera-Badillo, Francisco; Templeton, Arnoud; Tannock, Ian; Amir, Eitan // JNCI: Journal of the National Cancer Institute;Oct2015, Vol. 107 Issue 10, p1 

    A letter to the editor is presented in response to the article "Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis," by F. E. Vera-Badillo et al, published in a previous issue.

  • RE: Androgen Receptor Expression and Outcomes in Early Breast Cancer: A Systematic Review and Meta-Analysis. Yadong Wang; Haiyan Yang // JNCI: Journal of the National Cancer Institute;Oct2015, Vol. 107 Issue 10, p1 

    A letter to the editor is presented in response to the article "Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis," by F. E. Vera-Badillo et al, published in a previous issue is presented.

  • An Update on Breast Cancer Biomarkers. Becze, Elisa // ONS Connect;Feb2011, Vol. 26 Issue 2, p14 

    The article reports on the biomarkers which are being used as predictors of breast cancer outcomes, as healthcare providers can prescribe effective and personalized treatments in better way by identifying the presence of biomarkers in breast tumors. It is reported that, the three traditional...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics